Our new corporate presentation is now available to download. Listen to the video update from CEO, Nigel Theobald here. Key points covered in the presentation include:N4 Pharma's strategic focus on two key lead programs: N4 101 for Irritable Bowel Disease (IBD) and ECP 105 for post-surgical scarring preventionN4 Pharma's proprietary [...]
Pharma’s Almanac’s Q2 2024 roundtable ‘What are the current investment trends in the pharmaceutical industry and how are they influencing the sector’s direction?’ features a response from Nigel Theobald, CEO, N4 Pharma.Contributing to the discussion, Nigel highlights the need for investment into new non-lipid delivery systems like Nuvec® in [...]
Our latest article explores the challenges with targeting the gastrointestinal (GI) tract and outlines the current strategies aiming to unlock the potential of oral delivery for siRNA drugs targeted against GI diseases and cancers. We discuss why silica nanoparticles, such as Nuvec®, are one of the most promising siRNA [...]
Shares Magazine shines a spotlight on N4 Pharma (N4P:AIM), revolutionising biotech with advanced delivery systems for nucleic acids in oncology, gene therapy, and vaccines. Our patented mesoporous silica nanoparticles and newly acquired lipid-peptide delivery platform ensure precise, targeted treatment. We aim to become a leading supplier to major pharma [...]
Our latest news release for the trade media announces N4 Pharma’s research collaboration agreement with SRI, an independent non-for-profit research institute based in Silicon Valley, California, to combine Nuvec with SRI’s proprietary FOX Three Molecular Guidance System™ (MGS) to increase intercellular delivery to specific target cells. On the back of [...]
In an interview with World Pharma Today, Nigel Theobald, CEO N4 Pharma, answers questions about the company’s latest news and future plans. Key highlights from the discussion include: Acquisition: our recent acquisition of Nanogenics Limited and how it enhances our product offerings in gene therapy. Collaborative partnerships: our partnerships [...]
Our latest news release for trade media highlights our pre-clinical siRNA delivery systems Nuvec® and LipTide®. LipTide® is a lipid and peptide-based delivery system developed by Nanogenics and is currently being used in the formulation of a novel siRNA product, ECP105, which is targeting an unmet clinical need in [...]
In our latest article, we look at how the dual delivery of siRNA – via delivery systems such as Nuvec® – holds the potential to pave the way for a new era of improved efficiency in cancer treatment. Nuvec® has the potential to offer a solution that reduces the [...]
N4 Pharma’s Nuvec® platform has been independently appraised by Dr. Amy S. Rosenberg, Senior Director of Immunology and Protein Therapeutics at EpiVax. In the report Dr. Rosenberg assesses how N4 Pharma’s breakthrough Nuvec® platform might address the current shortcomings in cancer therapy. The novel silica nanoparticle delivery system can [...]
Our research partners at Brunel University London found that adenovirus (Av) – an effective gene delivery vehicle for vaccinations – complexed with Nuvec®, can significantly improve adenovirus transduction. In the study, researchers investigated the effect of using Nuvec to improve Av gene transfer. To identify the optimal concentration [...]
